FDA Approves LISRAYA (brepocitinib) for Adults with Dermatomyositis

The U.S. Food and Drug Administration (FDA) has approved LISRAYA™ (brepocitinib) 30 mg, a once-daily pill, for the treatment of adults with dermatomyositis (DM). This represents the first major therapeutic innovation in decades for this rare systemic autoimmune disease, which causes progressive muscle weakness and painful skin lesions. LISRAYA is a first-in-class TYK2/JAK1 inhibitor.